Terms: = Cervical cancer AND MALAT1, PRO1073, 378938, Q9UHZ2 AND Treatment
7 results:
1. Knockdown of lncRNA
Liang T; Lu T; Jia W; Li R; Jiang M; Jiao Y; Wang Y; Cong S; Jiang X; Dong L; Zhou Y; Zhang G; Xiao D
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37921054
[TBL] [Abstract] [Full Text] [Related]
2. iTRAQ-based quantitative proteomic analysis of the inhibition of cervical cancer cell invasion and migration by metformin.
Xia C; Yang F; He Z; Cai Y
Biomed Pharmacother; 2020 Mar; 123():109762. PubMed ID: 31864213
[TBL] [Abstract] [Full Text] [Related]
3. malat1 promotes cisplatin resistance in cervical cancer by activating the PI3K/AKT pathway.
Wang N; Hou MS; Zhan Y; Shen XB; Xue HY
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7653-7659. PubMed ID: 30536307
[TBL] [Abstract] [Full Text] [Related]
4. Long non-coding RNAs and cervical cancer.
Aalijahan H; Ghorbian S
Exp Mol Pathol; 2019 Feb; 106():7-16. PubMed ID: 30471246
[TBL] [Abstract] [Full Text] [Related]
5. Long non-coding RNAs on the stage of cervical cancer (Review).
Dong J; Su M; Chang W; Zhang K; Wu S; Xu T
Oncol Rep; 2017 Oct; 38(4):1923-1931. PubMed ID: 28849103
[TBL] [Abstract] [Full Text] [Related]
6. Effects of miRNA-143 and the non-coding RNA malat1 on the pathogenesis and metastasis of HeLa cells.
Zhang L; Niyazi HE; Zhao HR; Cao XP; Abudula MN; Ye WJ; Zhang SA; Yiming RH; Zhang Y; Su WP; Chen R; Ouyang Y; Miao N; Bao YX
Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28252165
[TBL] [Abstract] [Full Text] [Related]
7. LncRNAs: key players and novel insights into cervical cancer.
Peng L; Yuan X; Jiang B; Tang Z; Li GC
Tumour Biol; 2016 Mar; 37(3):2779-88. PubMed ID: 26715267
[TBL] [Abstract] [Full Text] [Related]
